New Jersey A 2240: Prohibits excessive increases in prices charged for essential off-patent and generic prescription drugs and biological products.

Status: Introduced in the Assembly, Referred to Assembly Health Committee (as of 2022-02-07)

State: New Jersey · Session: 220 · Bill: A 2240

Subjects: PHARMACEUTIC

Sponsors: Calabrese, Clinton, Murphy, Carol A.

View New Jersey A 2240 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.